natgillin/translations-raw huggingface dataset:
Patent US 6 426 632 disclose a system for generating current waveforms to test an arch fault protection and shortly describes the use of a microprocessor to detect the secondary current of a differential transformer and to compare it with thresholds stored in the microprocessor itself: if the detected current is greater than said thresholds the microprocessor sends a signal by which the relay is tripped and the connection with the mains is broken. 
Patent US 6 426 632 opisuje sustav za generiranje valnih oblika struje za ispitivanje zaštite od luka i ukratko opisuje upotrebu mikroprocesora za otkrivanje sekundarnu struju diferencijalnog transformatora i za komparaciju s pragovima koji su spremljeni u mikroprocesoru. Ako je registrirana struja veća od spomenutog praga, mikroprocesor šalje signal kojim se aktivira relej i prekida veza s vodovima.
Further, alkyl groups, as defined herein, may optionally be substituted on any available carbon atom with one or more functional groups commonly attached to such chains, such as, but not limited to hydroxyl, halo, haloalkyl, mercapto or thio, cyano, alkylthio, cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxyl, carbalkoyl, carboxamido, carbonyl, alkenyl, alkynyl, nitro, amino, alkoxy, aryloxy, arylalkyloxy, heteroaryloxy, amido, —OC(O)NR8R9, —OC(O)R8, —OPO3H, —OSO3H, and the like to form alkyl groups such as trifluoromethyl, 3-hydroxyhexyl, 2-carboxypropyl, 2-fluoroethyl, carboxymethyl, cyanobutyl and the like. 
Dalje, alkilne skupine, kao što je ovdje definirano, mogu biti opcijski supstituirane na bilo kojem dostupnom ugljikovom atomu sa jednom ili više funkcionalnih skupina koje su uobičajeno pričvršćene na takve atome, kao što su, ali nije ograničeno, hidroksil, halo, haloalkil, merkapto ili tio, cijano, alkiltio, cikloalkil, heterociklil, aril, heteroaril, karboksil, karbalkoil, karboksamido, karbonil, alkenil, alkinil, nitro, amino, alkoksi, ariloksi, arilalkiloksi, heteroariloksi, amido, -OC(O) NR*R", -OC(O)R*, -OPO;H, -OSO;H i slični koji tvore alkilne skupine kao što su trifluorometil, 3-hidroksiheksil, 2-karboksipropil, 2-fluoroetil, karboksimetil, cijanobutil i slično.
control condition 7, during the discharging of the universal rechargeable battery, the lithium-ion battery charging/discharging control circuit detects the temperature of the lithium-ion battery, and cutoffs the regulated voltage output when the temperature of the lithium-ion battery raises to a discharging upper threshold temperature TDH and restores the regulated voltage output when the temperature of the lithium-ion battery decreases to be lower than TDH−AT2, wherein TDH is a preset discharging upper threshold temperature of the lithium-ion battery, and AT2 is a preset backlash temperature corresponding to a backlash voltage of the TDH detection threshold; 
kontrolni uvjet 7, tijekom pražnjenja univerzalne punjive baterije, kontrolni krug za punjenje/pražnjenje litij-ionske baterije detektira temperaturu litij-ionske baterije, i prekida regulirani naponski izlaz kada temperatura litij-ionske baterije raste do gornjeg praga temperature TDH pražnjenja i uspostavlja regulirani naponski izlaz kada se temperatura litij-ionske baterije smanji kako bi bila niža nego TDH-AT2, gdje TDH je unaprijed podešeni gornji prag temperature pražnjenja litij-ionske baterije, a AT2 je unaprijed podešena temperatura mrtve zone koja odgovara naponu mrtve zone TDH praga za detekciju;
The method according to claim 1, wherein the cell line further comprises a human immunodeficiency virus-1 (HIV-1) tat gene stably integrated into its genome. 
Proizvođačka stanična linija prema zahtjevu 22 naznačena time da stanica nadalje sadrži barem jednu kopiju lentivirusnog tat gena stabilno integriranog u njezin genom
contacting the trans-(+)-A9-tetrahydrocannabinol from step (b) with trans-(−)-A9-tetrahydrocannabinol and a non-polar organic solvent to form the first composition. 
(c) kontaktiranje trans-(+)-A'-tetrahidrokanabinola iz koraka (b) sa trans-(-)-A'-tetrahidrokanabinolom i nepolarnim organskim otapalom da formiraju prvi sastav.
The antibody or antigen binding fragment thereof of Claim 1, wherein the antibody or antigen binding fragment thereof is an antibody fragment selected from the group consisting of Fab, Fab', Fab'-SH, Fv, scFv, F(ab')2, and a diabody. 
Antitijelo ili antigen-vežući fragment istog iz Zahtjeva 1, naznačeno time, što je antitijelo ili antigen-vežući fragment istog, fragment antitijela koji se bira iz grupe koja sadrži Fab, Fab', Fab'-SH, Fv, scFv, F(ab'),, 1 bispecifično antitijelo.
The exogenous metabolic-activation (S9) system consisted of an Aroclor 1254-induced rat-liver S9 (post-mitochondrial) fraction, as well as salts and cofactors. 
Egzogeni sustav aktivacije metabolizma (59) sastojao se od Aroclor 1254-inducirane 59 (post-mitohondrijalne) frakcije iz jetre štakora, kao i soli i kofaktora.
The process according to claim 9 comprising the step of terminal sterilization. 
Postupak u skladu s patentnim zahtjevom 11, naznačen time što se sastoji u koraku terminalne sterilizacije.
The device (1200) of claim 13, comprising: an interface to a user localization system for receiving the user density map. 
Naprava (1200) u skladu s patentnim zahtjevom 13, naznačena time što sadrži: međusklop prema sustavu za lokalizaciju korisnika za prijem karte gustoće korisnika.
Next, as shown in Figure 14, the 10-acetyl group is removed by hydrazinolysis. 
Nakon toga, kao što je prikazano na slici 14, 10-acetil skupina se ukloni pomoću hidrazinolize.
More specifically, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a renin inhibitor, preferably, a δ-amino-Y-hydroxy-w-aryl-alkanoic acid derivative, in combination with an efflux protein inhibitor, said efflux protein inhibitor being present in an amount such that, following administration, the bioavailability of a renin inhibitor is improved by at least 5%. 
Farmaceutski pripravak, naznačen time, da sadrži terapeutski učinkovitu količinu inhibitora renina u kombinaciji s inhibitorom istjecanja proteina, pri čemu je navedeni inhibitor istjecanja proteina prisutan u količini takvoj da se nakon primjene bioraspoloživost inhibitora renina poboljša najmanje 5%, pri čemu inhibitor renina je derivat amida t>&
or their pharmaceutically acceptable salts, enantiomers, racemates, prodrugs, derivatives or metabolites. 
- = baklofen, akamprozat i memantin, ili njihove farmaceutski prihvatljive soli.
a Cas9 polypeptide, or a nucleic acid comprising a nucleotide sequence encoding said Cas9 polypeptide; and 
polipeptid Cas9 ili nukleinska kiselina koja obuhvaća nukleotidnu sekvencu koja kodira polipeptid Cas9; i
Primary endpoint of the study was the occurrence of episodes of Candida reinfection, confirmed by fresh examination of the vaginal smear. 
Primarna završna točka istraživanja bila je pojava epizoda ponovne infekcije Candidom, što se potvrđivalo novim pregledom vaginalnog razmaza.
The use according to claim 9 for the prophylaxis and/or treatment of non-malignant hyperproliferative disorders and malignant hyperproliferative disorders, specifically of hepatocellular carcinoma, colon adenoma and polyposis, colon adenocarcinoma, breast cancer, pancreas adenocarcinoma, Barrett's esophagus and other forms of neoplastic diseases of the gastrointestinal tract and the liver. 
Uporaba prema patentnom zahtjevu 11 za profilaksu i/ili tretman ne-malignih hiperproliferativnih poremećaja 1 malignih hiperproliferativnih poremećaja, specifično hepatocelularnog karcinoma, adenoma debelog crijeva i polipoze, adenokarcinoma debelog crijeva, raka dojke, adenokarcinoma pankreasa, Barrett-ovog ezofagusa i drugih oblika neoplastičnih bolesti gastrointestinalnog trakta i jetre.
The pooling device of claim 6, wherein said fluid connection assembly [104] includes a second force-activated valve [184] being connected to said inlet port of said pooling device for selectively regulating a directional fluid flow of the fluid. 
Uređaj za objedinjavanje prema zahtjevu 6, naznačen time što navedeni sklop za spajanje fluida [104] sadrži drugi ventil koji se aktivira silom [184] koji je spojen na navedeni ulazni otvor navedenog uređaja za objedinjavanje radi selektivnog reguliranja usmjerenog fluidnog strujanja fluida.
The process according to claim 1, wherein, in the conversion of the compound of formula (V) into the compound of formula (I), the transition metal is nickel, palladium or platinum. 
Postupak za industrijsku sintezu spoja formule (D) u skladu s patentnim zahtjevom 1, naznačen time, da je kod pretvaranja spoja formule (V) u spoj formule (1), prijelazni metal nikal, paladij ili platina.
at least 60% of the cells in the population express on their surfaces detectable levels of CXCR2 and 
(xi) najmanje 60 % stanica u populaciji na svojoj površini izražava uočljive razine CXCR2 1
Use according to claims 8 - 12 characterized in that the active ingredients are presented in an inhaler 
Uporaba u skladu s patentnim zahtjevima 8-12, naznačena time, da su djelatni sastojci predstavljeni u inhalatoru.
A pharmaceutical composition comprising the monoclonal antibody or antigen-binding fragment thereof according to claim 1, and a pharmaceutically acceptable vehicle, carrier or diluent. 
Polipeptid prema zahtjevu 1, naznačen time što je sekvenca prikazana u SEQ ID NO: 35, ili varijanta polipeptida koja je najmanje 85% identična cijeloj duljini SEQ ID NO: 35.
The compounds TPI 287, TPI 285 and TPI 251 are discussed in greater detail below and have the following respective structures: 
O spojevima TPI 287, TPI 285 1 TPI 251 se raspravlja detaljnije u daljnjem tekstu, pri čemu oni imaju sljedeće odgovarajuće strukture:
the second fragment is a toxin B repeating domain fragment and comprises at least 100 amino acids; 
drugi fragment je fragment ponavljajuće domene toksina B iz bakterije C. difficile;
and/or for the manufacture of monolithic lining, precast shapes, prefabricated elements, functional products, fireproof products and/or insulating products for furnaces, vessels or other devices used in the refractory, steel, non-ferrous metals, cement, glass, ceramic, electronic, construction, and other industries. 
Uporaba refraktornog materijala koji sadrži magnezijski cement definiran prema bilo kojem od zahtjeva 13 do 1,6 za proizvodnju monolitne obloge, montažnih oblika, montažnih elemenata, funkcionalnih proizvoda, proizvoda otpornih na vatru i/ili izolirajućih proizvoda za peći, posuda ili drugih uređaja koji se koriste u refraktornim, čeličnim, ne-željeznim metal, cementnim, staklenim, keramičkim, elektroničkim, konstrukcijskim i ostalim industrijama.
The humanized anti-human a9 integrin antibody described in (1) above, wherein the heavy chain consists of the amino acid sequence shown by SEQ ID NO:19 and the light-chain consists of the amino acid sequence shown by SEQ ID NO:25. 
Humanizirano anti-humani-alfa9-integrin-protutijelo prema zahtjevu 1, naznačeno time, da se jaki lanac sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:19 i slabi lanac se sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:25.
A process according to claim 1, wherein the spherical polymer particles have a particle size distribution in the range from 0.5 to 2.0. 
Postupak prema barem jednom od zahtjeva 1 do 7, naznačen time što polimerne čestice imaju raspodjelu veličine čestica u rasponu od 0.5 do 2.0.
Use of a compound according to claim 1, a salt thereof or a hydrate of the foregoing, for the preparation of a medicament for inhibiting cancer metastasis. 
Uporaba spoja prema zahtjevu 1, njegove soli ili hidrata, naznačena time da je za pripremu lijeka za inhibiciju metastaze karcinoma.
a cover, said base part and cover being sealingly interconnectable; a base unit comprising 
- < pokrov, pri čemu se spomenuti osnovni dio i pokrov mogu međusobno spojiti nepropusno;
Isolated nucleic acid encoding an anti-beta7 antibody according to claim 1. 
Izolirana nukleinska kiselina, naznačena time, da kodira humanizirano protutijelo anti-beta7, te obuhvaća;
Particularly preferred is an extended release tablet formulation, wherein the substantially neutral polymer is hydroxypropyl methylcellulose, and wherein the content of hydroxypropyl methylcellulose in the matrix is from about 10 wt.-% to about 75 wt.-% and preferably from about 25 wt.-% to about 65 wt.-%. 
Formulacija tablete produljenog oslobađanja u skladu sa zahtjevom 4, naznačena time, da u biti neutralan polimer je hidroksipropilmetilceluloza, te pri čemu sadržaj hidroksipropilmetilceluloze u matrici je od oko 10 mas. % do oko 75 mas. %, te je povoljnije od oko 25 mas. % do oko 65 mas. %.
A method according to any preceding claim wherein the compound of formula (III) is formed by a method comprising reacting a compound of formula (II) with a compound of formula (VIII): wherein R6 is a C1-5 fluoroalkyl. 
Postupak sukladno bilo kojem od prethodnih zahtjeva, naznačen time što se spoj formule (III) stvara postupkom koji sadrži reakciju spoja formule (II) sa spojem formule (VIII): R*-5-o-R' O
The solid oral extended release pharmaceutical dosage form of claim 1, wherein the composition comprises 32 mg hydromorphone hydrochloride, and wherein the composition comprises at least about 90 % (by wt) polyethylene oxide. 
Postupak prema zahtjevu 37, naznačen time da je opioidni analgetik hidromorfon hidroklorid i da oblik davanja sadrži od oko 1 mg do oko 100 mg hidromorfon hidroklorida.
An acid addition salt according to claim 1, a combination according to any one of claims 2 to 8, or a composition according to claim 9 for the treatment of stroke. An acid addition salt according to claim 1, a combination according to any one of claims 2 to 8, or a composition according to claim 9 for use as a neuroprotective agent. 
Kombinacija sukladno bilo kojem od patentnih zahtjeva 1 do $, ili pripravak sukladno patentnom zahtjevu 9 za liječenje boli, moždanog udara, uporaba kao neuroprotektivno sredstvo, uporaba kao protutigljivično sredstvo, uporaba kao antiprotozoalno sredstvo, ili za uporabu kao antiparazitsko sredstvo.
The expansion joint according to claim 1, wherein the first vertically oriented corrugated plate of the upper portion and the first vertically oriented corrugated plate of the lower portion are in substantially the same lateral plane. 
Kompenzacijski spoj prema zahtjevima 10 -11, naznačen time da je navedena druga valovita ploča (17) od donjeg dijela u istoj bočnoj ravnini kao i druga valovita ploča (6) gornjeg dijela.
Process for the production of alcohol and/or solvent from a biomass feedstock, in which the following stages are carried out: 
POSTUPAK ZA PROIZVODNJU ALKOHOLA I / ILI OTAPALA IZ BIOMASE UZ ISPIRANJE LIGNOCELULOZNOG ČVRSTOG OSTATKA NAKON HIDROLIZE HR P20191553 T1
A compound of Claim 2 wherein R3 and R4 are taken together with the contiguous linking nitrogen and carbon atoms to form an optionally substituted ring R-2; and Z is CH=CH or CH=CF, provided that the CH=CF moiety is oriented so the carbon atom bonded to F is connected as R3 in Formula 1 . 
Spoj prema patentnom zahtjevu 2, naznačen time što Ri R* su uzeti zajedno sa kontinuiranim vezujućim atomima dušika i ugljika tako da formiraju izborno supstituirani prsten R-25 i Z je CH=CH ili CH=CF, uz uvjet da je CH=CF grupa orijentirana tako da je atom ugljika koji je vezan za F spojen kao Rž u formuli 1.
The ladle in accordance with any one of the preceding claims, wherein the ladle shell and the ladle liner have substantially the same shape 
Posuda za lijevanje prema bilo kojem od prethodnih zahtjeva, pri čemu omotač posude za lijevanje i obloga posude za lijevanje imaju u biti isti oblik
In a preferred embodiment, the invention relates to a protein or polypeptide or peptide which comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 12-14, and 146-150, a part or derivative thereof. 
Primjena prema bilo kojem od zahtjeva 6 do 8, pri čemu se antitijelo može dobiti imunizacijom uz korištenje proteina, peptida ili polipeptida koji sadrže aminokiselinsku sekvencu izabranu iz grupe koja se sastoji od SEQ ID NOs: 16-19, 1121113.
mannitol) or chemical stability (e.g. 
manitol) ili kemijsku stabilnost (pr.
Preferably, the transformation is effected to an extent of at 80% within 10-100 sec, such as within 20-60 sec. 
Preferirano je transformacija dosegla 80% unutar 10-100 sekundi, kao što je unutar 20-60 sekundi.
aryl is a homocycle selected from phenyl, naphthyl, acenaphthyl or tetrahydronaphthyl, each being optionally substituted with 1, 2 or 3 substituents, each substituent being independently selected from hydroxy, halo, cyano, nitro, amino, mono- or dialkylamino, alkyl, haloalkyl, alkyloxy, haloalkyloxy, carboxyl, alkyloxycarbonyl, aminocarbonyl, morpholinyl or mono- or dialkylaminocarbonyl. 
je homocikal odabran između fenila, naftila, acenaftila ili tetrahidronaftila, svaki po izboru je supstituiran sa L, 2 ili 3 supstituenta, svaki supstituent je nezavisno odabran između hidroksi, halo, cijano, nitro, amino, mono-ili dialkilamino, alkila, haloalkila, alkiloksi, haloalkiloksi, karboksila, alkiloksikarbonila, aminokarbonila, morfolinila ili mono- ili dialkilaminokarbonila.
and from 1 to 3% by weight, related to a solid matter content, of plasticizing agent and/or up to maximum 1%, related to the solid matter content, stabilizer, wherein said curable binder is in the form of an aqueous solution. 
[f) iod 1 do 3% težine, u odnosu na sadržaj krute tvari kod sredstva za plastificiranje i / ili do maksimalno 1%, u odnosu na sadržaj krute tvari, stabilizator, pri čemu je navedeno učvršćujuće vezivo u obliku vodene otopine.
electrically driving the active load so as to at least reduce current flowing in the active load at an end of the validation of the candidate signal. 
električnom pogonjenju (209) aktivnog tereta (50) kako bi u najmanju ruku oslabio struju koja ide u aktivni teret (50) na kraju provjere kandidatnog signala (S).
A compound according to any one of Claims 1 to 5, or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, stereoisomer, mixture of stereoisomers or tautomer thereof, or a pharmaceutical composition according to Claim 6 for use in a method for treating a disease or condition selected from the group consisting of an inflammatory disorder, an allergic disorder, an autoimmune disease, and a cancer. 
Spoj sukladno bilo kojem od patentnih zahtjeva 1 do 5, ili njegova farmaceutski prihvatljiva sol, farmaceutski prihvatljiv kokristal, stereoizomer, mješavina stereoizomera ili tautomer, ili farmaceutski pripravak sukladno patentnom zahtjevu 6 za uporabu u postupku liječenja bolesti ili stanja odabranog iz skupine sastavljene od inflamatornog poremećaja, alergijskog poremećaja, autoimune bolesti i karcinoma.
connecting an auxiliary extraction line on one side of the assembly in a position above the inlet line for supplying injection material to the assembly, 
- < dovođenje injekcijskog materijala do pomoćne injekcijske linije (25) na jednoj strani sklopa (3),
The compound, salt, or composition of claim 18, wherein said cancer is selected from cancer of the colon, pancreatic cancer, breast cancer, prostate cancer, lung cancer, brain cancer, ovarian cancer, cervical cancer, testicular cancer, renal cancer, cancer of the head and neck, lymphoma, leukemia, and melanoma. 
Spoj ili sol za upotrebu prema zahtjevu 1, pri čemu je spomenuti rak izabran od raka debe1og crijeva, raka gušterače, raka dojke, raka prostate, raka pluća, raka mozga, raka jajnika, cervikalnog raka, raka testisa, raka bubrega, raka glave i vrata, limfoma, leukemije i me1anoma.
A compound according to any one of claims 1 to 5, for use in the treatment of abnormal fat-distribution and conditions or disease associated therewith. 
Spoj sukladno bilo kojem od zahtjeva 1 do 5, za uporabu u liječenju abnormalne distribucije masnog tkiva te povezanih stanja i bolesti.
The hydrophobic core has a major impact on the uniqueness and stability of the Ig fold. 
Hidrofobna jezgra ima snažan utjecaj na jedinstvenost i stabilnost konformacije imunoglobulinske domene.
The dehydrogenation process according to anyone of claims from 1 to 5, wherein in said catalytic composition the oxides of alkaline metals are K2O. 
Katalitička smjesa u skladu s patentnim zahtjevima 1 ili 2, naznačena time što su oksidi alkalnih metala K2O.
and at least one phosphate salt. 
(ID i b) najmanje jednu fosfatnu sol.
Compound of following general formula (I): in which: 
PATENTNI ZAHTJEVI Spoj sljedeće opće formule (I):
a mass suitable to be subjected by the driving means to an alternate motion, namely a mass oscillating substantially along the direction of a vertical axis (Z) and comprising at least one restricted environment where substances in a solid and/or liquid state receive a physical or chemical-physical treatment by kinetic energy of milling bodies (14; 89); 
- masa koju se može podvrgnuti pogonu kako bi se postiglo promjenjivo gibanje, naime masa koja oscilira uglavnom u smjeru okomite osi (Z) i sadrži najmanje jedan ograničeni okoliš gdje se na tvarima u čvrstom ifili tekućem stanje vrši fizička ili fizičko-kemijska obrada kinetičkom energijom tijela za mljevenje (14; 89);
Disposal lock (1) according to one of the preceding claims, wherein, as seen in the vertical direction of the container, two closure elements are provided for determining various holding volumes in the container. 
Brana za uklanjanje otpada (1) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što, kao što se vidi u okomitom smjeru spremnika, ima drugi element za zatvaranje, namijenjen određivanju različitih volumena za držanje u spremniku (18).
At present, a fairly large number of methods and apparatuses are known that allow enhancement of production processes for high-viscosity oils. 
Trenutno je poznat prilično velik broj metoda i uređaja koji omogućuju poboljšanje proizvodnih postupaka za naftu visoke viskoznosti.
producing the sum of the telomere component, the dosage component and a constant; and 
računanje zbroja komponenti telomere, komponente doze i konstante; i
The iso -propanol solvate according to claim 3 wherein said crystalline solvate exhibits an X-ray powder diffraction pattern comprising at least one peak selected from the group consisting of 20.6, 26.6, 27.2, 28.3, and 29.3 degrees 2θ ± 0.1 degrees 2θ and optionally further comprises at least two peaks selected from the group consisting of 25.0, 26.0, 26.6, 27.2, 28.3, and 29.3 degrees 2θ ± 0.1 degrees 2θ or further comprises at least one peak selected from the group consisting of 10.8, 14.0, 21.1, 21.9, and 22.5 degrees 2θ ± 0.1 degrees 2θ, and optionally wherein said crystalline solvate exhibits a solid state 13C NMR spectrum comprising peaks at 63.1 and 140.7 ppm ± 0.2 ppm. 
Izopropanol-solvat prema zahtjevu 3, naznačen time, da navedeni kristalni solvat prikazuje uzorak difrakcije praha X-zraka koji obuhvaća barem jednu vršnu vrijednost odabranu iz skupine koja se sastoji od 20,6, 26,6, 27,2, 28,3 i 29,3 stupnjeva 2θ ± 0,1 stupanj 2θ i opcijski nadalje obuhvaća barem dvije vršne vrijednosti odabrane iz skupine koja se sastoji od 25,0, 26,0, 26,6, 27,2, 28,3 i 29,3 stupnjeva 2θ ± 0,1 stupanj 2θ ili dodatno obuhvaća barem jednu vršnu vrijednost odabranu iz skupine koja se sastoji od 10,8, 14,0, 21,1, 21,9 i 22,5 stupnjeva 2θ ± 0,1 stupanj 2θ te opcijski, da navedeni kristalni solvat izlaže kruto stanje 13C NMR-spektra gdje obuhvaća vršne vrijednosti na 63,1 i 140,7 ppm ± 0,2 ppm.
The capsule of claim 21 wherein up to 4500 mg amoxicillin and up to 300 mg rifabutin is administered daily. 
Kapsula u skladu s patentnim zahtjevom 21, naznačena time što se svakodnevno primjenjuje do 4500 mg amoksicilina i do 300 mg rifabutina.
reacting the compound of formula (IV), or a salt thereof, with N-hydroxysuccinimide in the presence of a base to form a salt of the compound of formula (V); and 
(M ili njegova sol; b) reakciju spoja formule (IV), ili njegove soli, s N-hidroksisukcinimidom u prisutnosti baze, da se dobije sol spoja s formulom (V); i